New combo therapy aims to stop liver cancer recurrence in High-Risk patients
Disease control
Completed
This study tested whether adding rivoceranib to camrelizumab (a type of immunotherapy) works better than camrelizumab alone to keep liver cancer from returning after surgery or ablation. It involved 251 patients with hepatocellular carcinoma at high risk of recurrence. The main g…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC